• Mid Atlantic Bio Angels 1st Pitch Life Science-Philadelphia

“

“Eavesdropping on investors‘ closed door discussions” gives entrepreneurs the inside track on what happens after a start-up company presents to investors.  Typically, after a start up company’s team leaves the room investors have a private discussion about whether the opportunity merits further investigation and possible investment.  1st Pitch Life Science-Philadelphia offers local company presenters and audience participants the chance to listen in on these closed door discussions to learn what really matters to investors.  This event offers excellent networking opportunities for investors, university technology transfer professionals, entrepreneurs, and business professionals in the Philadelphia entrepreneurial ecosystem.   It provides a supportive learning environment for entrepreneurs.

                                                                                                                                                                                                    “

For more information about Mid-Atlantic BioAngels and to make a submission for evaluation of your startup please visit their

website: http://bioangels.net/.

MABA: LinkedIn:
MABA: Twitter

Mid-Atlantic Bioangels was formed in 2013 to provide an unmet need in the Mid-Atlantic region for early-stage life-science entrepreneurship,  providing early life science entrepreneurs a venue to  present their companies, obtain funding and provide mentoring, feedback, networking, and information for corporate development.  A great article by Kira M. Newman can be found here

http://tech.co/mid-atlantic-bio-angels-life-sciences-investors-2013-06

More information on the !st Pitch Life Sciences meetings can be found at www.1stpitchlifescienc.com.  Further information can be obtained at nfo@1stpitchlifescience.com.For sponsorship questions please email Bernie@bioangels.net.

Meeting Coverage

Three companies are to be presented

Hastke Inc is a device company with a best-in-class, real-time 3D visualization technology that can de-risk the drug development process for pharma.  In the future, their technology has the potential to become an important diagnostic tool for physicians.

LytPhage is a new biotech company using novel bioengineering to develop therapeutics to address the worldwide crisis of antibiotic resistant organisms.  They are developing a treatment for vancomycin resistant systemic infections with their platform, which can be adapted for other problematic organisms.

RAbD Biotech uses proprietary computational methods to design biologic agents capable of treating severe diseases.  RAbD’s lead product candidate is a potential first-in-class treatment for ovarian cancer, a disease characterized by late detection, few therapeutic options, and high mortality.

The meeting format includes:

1. 15-20 minute meeting presentation
2. group discussion/questions
3. panel opinions (panel of experienced venture capitalists)

Notes from the meeting will be put in future postings.

Please also see Twitter handles for meeting coverage using the following hashtags and handles

hashtags                                                                                                   handles

             #MABA   #lifescience   #PHL   #biotech         #startup                                @BioAngelsGroup   @pharma_BI   @RAbDBiotech

              #VC  #venturecapital   # bioangels    #entrepreneur

              #angelinvestor 

The meeting had a live voting on Surveymonkey for each presentation using your smartphone.  The address for the voting was

www.1stpitchlifescience.com/vote

where event participants vote on each individual presentation and a “Best in Show”.